[Skip to Content]
[Skip to Content Landing]
Views 97
Citations 0
Correction
October 2016

Missing Reference Citation

JAMA Intern Med. 2016;176(10):1579. doi:10.1001/jamainternmed.2016.5900

There were several errors in the editorial by Butler titled “Glucagon-like Peptide 1 Drugs as Second-line Therapy for Type 2 Diabetes,”1 published online August 1, 2016. A citation to the reference by Marso et al (Marso SP, Daniels GH, Brown-Frandsen K, et al; LEADER Steering Committee on Behalf of the LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes [published online June 13, 2016]. N Engl J Med. doi:10.1056/NEJMoa1603827) has been added to the second-to-the-last sentence of the first paragraph; it now reads: “This benefit has recently been reported in a placebo control randomized clinical trial (RCT) for the GLP-1 agonist Liraglutide (Victoza) (A).1” The reference list was renumbered accordingly. This article has been corrected online.

References
1.
Butler  PC.  Glucagon-like peptide 1 drugs as second-line therapy for type 2 diabetes  [published online August 1, 2016].  JAMA Intern Med. 2016. doi:10.1001/jamainternmed.2016.1523PubMed
×